A Study of the Safety and Effectiveness of Galantamine Hydrobromide (REMINYL ) in Patients With Alzheimer's Disease - Full Text View - ClinicalTrials.govThe purpose of this study is to evaluate the safety and effectiveness of galantamine hydrobromide (REMINYL ) in patients with Alzheimer's disease who have not received or have not responded to treatment with medication similar to galantamine hydrobromide (REMINYL ).Galantamine hydrobromide (REMINYL ) is a medication that is approved for the treatment of symptoms of Alzheimer's disease. In accordance with international guidelines, studies are conducted after a drug is marketed to continue to evaluate and expand the knowledge regarding its safety. This is a multi-center, open-label observational study to collect information regarding the safety and effectiveness of galantamine in patients with Alzheimer's disease. Patients who have been prescribed galantamine hydrobromide (REMINYL ) as initial treatment with this type of medication for their Alzheimer's disease or who have failed previous treatment with similar medication of this type for their Alzheimer's disease will receive galantamine for 6 months.
